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Background: In Mozambique, antiretroviral therapy (ART) scale-up has been successfully implemented.
However, attrition in care remains a major programmatic challenge. In 2009, an intermediary-level HIV
referral center was created in Maputo to ensure access to specialized care for HIV-infected patients with
complications (advanced clinical-immunological stage, Kaposi sarcoma, or suspected ART failure).
Objective: To determine the attrition from care and to identify risk factors that lead to high attrition among
patients referred to an intermediary-level HIV referral center.
Design: This was a retrospective cohort study from 2009 to 2011.
Results: A total of 1,657 patients were enrolled, 847 (51%) were men, the mean age was 36 years (standard
deviation: 11), the mean CD4 count was 27 cells/ml (interquartile range: 1144), and one-third were severely
malnourished. The main reasons for referral were advanced clinical stages (WHO stages 3 and 4, and CD4
count B50 cells/ml) in 70% of the cases, and 19% had Kaposi sarcoma. The overall attrition rate was 28.7 per
100 person-years (PYs)  the mortality rate was 5.0 (95% confidence interval [CI]: 4.25.9) per 100 PYs, and
the loss-to-follow-up rate was 23.7 (95% CI: 21.925.6) per 100 PYs. There were 793 attritions  137 deaths
and 656 lost to follow-up (LTFU); 77% of all attrition happened within the first year. The factors
independently associated with attrition were male sex (adjusted hazard ratio [aHR]: 1.15, 95% CI: 1.01.3),
low body mass index (aHR: 1.51, 95% CI: 1.21.8), WHO clinical stage 3 or 4 (aHR: 1.30, 95% CI: 1.01.6;
and aHR: 1.91, 95% CI: 1.42.5), later year of enrollment (aHR 1.61, 95% CI 1.31.9), and ‘being already on
ART’ at enrollment (aHR 13.71, 95% CI 11.416.4).
Conclusions: Attrition rates among HIV-infected patients enrolled in an intermediary referral center were
high, mainly related to advanced stage of clinical disease. Measures are required to address this, including
innovative strategies for HIV-testing uptake, earlier ART initiation and nutritional supplementation, and
special attention to men and those who are already on ART at enrolment. Qualitative research is required to
understand the reasons for being LTFU and design informed evidence-based interventions.
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I
n Mozambique, a resource-poor country in southern
Africa, HIV infection continues to be a major public
health problem. An estimated 1.6 million people are
living with HIV/AIDS which remains the leading cause
of death in adults aged 1549 years in the country (1, 2).
Over the last 10 years, the national HIV/AIDS program
has made remarkable efforts to combat the HIV epi-
demic, with a rapid decentralization of services to lower-
level health facilities across the country in order to scale
up access to antiretroviral treatment (ART).
While the success of the ART scale-up has been well
documented globally, attrition (death, lost to follow-up
[LTFU], and stopping ART) among patients in care
remains a major programmatic challenge (3, 4). Previous
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attrition before and after initiation of ART, with most
patient attrition occurring within the first year after ART
initiation, and rates have been found to be higher in
peripheral health clinics as compared to vertically im-
plemented urban HIV clinics (5, 6). Possible reasons for
this high attrition could be related to the lack of capacity
to manage complicated cases of HIV and the lack of
secondary-level referral centers in some health districts
for the management of such cases (7).
In order to bridge the gap, Me ´decins Sans Frontie `res
(MSF), in collaboration with the Ministry of Health of
Mozambique, created an intermediary-level HIV care
center (the Referral Centre of Alto Mae [CRAM]) in
Chamanculo Health District (CHD) in Maputo City to
ensure access to specialized care for patients living with
HIV who had complications (including those with low
CD4 counts, with advanced clinical stage, with Kaposi
sarcoma, and/or in need of second-line ART). Thus,
the patient cohort in CRAM was already at a higher risk
of attrition. To add to the concern, annual program
reports indicated an increasing trend of attrition from
24% in 2009 to 32% in 2011 (8). Hence, a good under-
standing of the pattern and causes of attrition is needed
to improve program performance, contribute to patient
survival, and reduce the risk of further HIV transmission
in the community (9). In this study, we aimed to describe
the overall attrition rates among patients living with
HIV and enrolled in CRAM, discuss the timing of such
attrition, and determine the clinical and demographic
factors associated with attrition.
Methods
Design
This is a retrospective cohort study using routine pro-
gram data.
Study setting
CHD is located in the southern part of Maputo City,
Mozambique, and has a total population of 329,872
inhabitants. The CRAM is an intermediary-level health
facility that has four outpatient consultation rooms,
a three-bed day-care unit, and a Kaposi sarcoma unit.
CRAM serves as the only referral center for complicated
HIV cases out of the five primary health centers of the
CHD. Patients who fulfill the referral criteria (see Box 1)
are received at CRAM and cared for until their condi-
tion becomes stable (defined as having a CD4 count of
more than 200 cells/ml and showing no signs of ther-
apeutic failure, adherence problems, or opportunistic
infections [OIs] for more than 6 months). The patients
are then referred back to their original health center
with a medical summary that contains all the relevant
information regarding patient treatment and care re-
ceived at CRAM. Patients requiring admission and
intensive care are immediately referred to tertiary care
hospitals.
PHC, primary health care; CRAM, Referral Centre of Alto Mae,
Maputo City, Mozambique; OI, opportunistic infection; ART,
antiretroviral therapy.
CRAM provides a comprehensive package of medical,
laboratory, and psychological care, including second- and
third-line ART for adults and children, chemotherapy
for patients living with HIV and Kaposi sarcoma, and
the diagnosis and treatment of OIs, side effects of ART
drugs, psychiatric diseases, and other conditions. The
center also provides psychosocial support, which includes
counseling to enhance adherence, special psychological
support for patients presenting with Kaposi sarcoma, and
psychological care for those patients in need. A system
for tracing those LTFU through phone calls and direct
home visits has also been established. At the end of 2012,
about 1,470 patients were enrolled on care, including
more than 400 Kaposi sarcoma patients and around 250
patients in second line ART, making the CRAM one of
the most important treatment centers for Kaposi sarcoma
and second-line ART care in the country. During the
study period, the Mozambican national guidelines (10)
specified the eligibility criteria for ART initiation as ful-
filling at least one of the following: 1) WHO stage 4, 2)
WHO stage 3 and CD4 count B350 cells/ml, or 3) CD4
countB250 cells/ml irrespective of WHO stage.
Study population
The study population includes all patients living with
HIV who enrolled in the CRAM from January 1, 2009,
to December 31, 2011. The study was conducted during
MarchNovember 2013. In this study, patients were
followed till 31 March 2013 (the censor date).
? BOX 1. Criteria for referral of patients from PHC to
CRAM referral center in Maputo, Mozambique
. Patients with CD4 less than 50 cells/ml and with
signs of severe OI
. Patients in suspicion of ART first-line treatment
failure
. Pediatric complex cases living with HIV
. Patients with Kaposi sarcoma eligible for
chemotherapy
. Co-infection of HIV-1 with human T-lympho-
tropic virus (HTLV) or hepatitis B/C and HIV-2
. Patients suffering from side effects of ART treat-
ment, including lactic acidosis
. Patients in critical health condition, lacking com-
plementary examinations, and in need of more
specialized care or invasive medical procedures.
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The variables related to the study objectives, includ-
ing age, sex, baseline body mass index (BMI; defined as
the individual’s body weight in kilograms divided by the
square of their height in meters [kg/m
2]), WHO clinical
staging, Kaposi sarcoma (clinical diagnosis), ART status
at time of presentation, ARTregimen, year of enrollment,
attrition (defined as discontinuation from care for any
reason, including death, LTFU, and stopping ARV
medications), and dates of enrollment and attrition,
were extracted from the program’s electronic database
(FUCHIA; Epicentre, Paris, France) and exported for
analysis. LTFU was defined as patients who did not
return to the facility for a period of 60 days or more after
their last scheduled appointment.
We used EpiData Analysis (version 2.2.2.182; EpiData
Association,Odense,Denmark)andSTATA(version12.1;
STATA Corp., College Station, TX, USA) for univariate
and multivariate analysis, respectively. Time-to-event ana-
lysis was performed. Time was measured from the date
of enrollment in CRAM to the date of attrition or censor
date, whichever was earlier. We calculated attrition rates
(death rates and LTFU rates) by adding the patients
who discontinued careanddividing by thetotal numberof
person-years (PYs) of observation, expressed as rates
per 100 PYs along with 95% confidence intervals (95%
CI). To examine associations of attrition with demo-
graphic and clinical characteristics, hazard ratios with
95% confidence intervals were calculated. KaplanMeier
survival curves (showing a cumulative incidence of attri-
tion) were plotted to examine the differences across the
strata of demographic and clinical factors. A log rank test
was used to assess difference between the area under
the curves, and a P-value less than 0.05 was considered
statistically significant. Life tables were computed to
calculate cumulative incidence of attrition at 1, 3, 6, and
12 months and 2, 3, and 4 years after enrollment. All
the variables found to be statistically significant during
bivariate analysis were used for a multivariate analysis
using a Cox proportional hazard regression model,
and adjusted hazard ratios (aHRs) were calculated to
assess the independent effects of each variable after
controlling for the confounding effect of other variables.
The proportional hazard assumption was assessed using
the Schoenfeld and scaled Schoenfeld residuals and log
log plots.
Ethics approval
The study was approved by the Mozambican Ethical
Review Committee and has met the MSF’s (Geneva,
Switzerland) Ethics Review Boardapproved criteria for
analysis of routinely collected program data. It also
satisfies the requirements of the Ethics Advisory Group
of the International Union Against Tuberculosis and
Lung Disease (Paris, France) and has their approval.
Results
A total of 1,657 patients were enrolled in care during
the study period. Of them, 847 (51%) were men, and the
mean (standard deviation) age was 36 (SD: 11) years.
Table 1 shows the demographic and clinical character-
istics of the individuals included in this analysis. The
main reasons for referral to CRAM were that the patients
were in advanced clinical stages (WHO stages 3 or 4,
Table 1. Attrition rates by demographic and clinical char-
acteristics among clients living with HIV and enrolled for
care in Maputo, Mozambique, 20092011
Category Subcategory
Number
(%)
Attrition
rate per
100 PY (95% CI)
Total  1,657 (100) 28 (2630)
Sex Male 847 (51) 32 (2936)
Female 808 (49) 24 (2227)
Unknown 2 (0) 29 (4208)
Age (years) B25 143 (9) 30 (2438)
2534 730 (44) 28 (2531)
3544 414 (25) 25 (2230)
]45 361 (22) 32 (2837)
Unknown 9 (1) 21 (857)
Kaposi
sarcoma
Yes 314 (19) 41 (3548)
No 1,343 (81) 27 (2529)
WHO stage 1 249 (15) 19 (1524)
2 257 (16) 17 (1421)
3 557 (34) 25 (2228)
4 584 (35) 46 (4151)
Not recorded 10 (1) 29 (1271)
CD4 count B50 346 (21) 15 (1217)
50249 40 (2) 14 (825)
250349 13 (1) 34 (1769)
 350 16 (1) 25 (1349)
Unknown 1,242 (75) 36 (3339)
BMI (kg/m
2) B16 186 (11) 45 (3854)
1618.5 334 (20) 30 (2635)
]18.5 939 (57) 21 (1923)
Unknown 198 (12) 61 (5273)
ART status at
the time of
presentation
Yes 247 (15) 627 (553712)
No 1,410 (85) 20 (1922)
ART regimen* First-line 1,356 (96) 20 (1922)
Second-line 54 (4) 17 (1027)
Year of
admission
2009 590 (36) 19 (1721)
2010 407 (25) 28 (2433)
2011 660 (40) 47 (4253)
100 PYs, 100 person-years of observation; CI, confidence
interval; WHO, World Health Organization; BMI, body mass
index; ART, antiretroviral therapy.
*Only for those in whom ART was initiated at the study site and
information was available.
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and 19% (314) had Kaposi sarcoma. Nearly one-third
were severely malnourished. Data on CD4 counts were
missing in nearly three-fourths of patients. Among those
with known CD4 counts, the median was 27 cells/ml
(interquartile range: 1144). Nearly 85% of all the
patients were not on ART at the time of presentation
and were initiated on ART at CRAM. Among them,
nearly 96% were started on a first-line ART regimen,
while the rest were put on second-line or alternate first-
line ART.
The attrition rates among the study population
are shown in Table 2. The patients contributed to a total
observation period of 2,762 PYs, during which 793
attrition events occurred: 137 deaths and 656 LTFU.
Thus, the overall attrition rate was 28.7 per 100 PYs,
where the mortality rate contributes 5.0 (95% CI: 4.25.9)
per 100 PYs and LTFU rate contributes 23.7 (95% CI:
21.925.6) per 100 PYs. Attrition rates were significantly
higher among men, those with Kaposi sarcoma, people in
WHO clinical stage 3 or 4, those with low BMI, and
people enrolled in care during the year 2010 and 2011.
The highest attrition rates were observed among those
who were already on ART at the time of presentation to
the clinic.
The cumulative incidence of attrition and its timing
are shown in Table 2. It is to be noted that nearly 77%
of all attrition happened within the first year of enroll-
ment, and of the attrition during the first year, about 50%
occurred during the first month  this was similar for
deaths and LTFU.
Since most of the attrition was contributed by LTFU
patients and previous studies have shown that nearly 50%
of LTFU patients actually died, we decided to examine
overall attrition rates as the outcome variable. Table 3
shows the Cox proportional hazard regression analysis
of factors associated with attrition. The factors inde-
pendently associated with attrition after simultaneous
adjustment of all confounders were male sex, low BMI,
WHO clinical stage 3 or 4, and later year of enroll-
ment (Fig. 1), and ‘being already on ART’ at the time
of presentation to the clinic was the most significant
factor (Fig. 2).
Discussion
To our knowledge, this is one of the first analyses of
attrition from care focused on patients living with HIV
and with advanced disease who were enrolled in an
intermediary-level health facility. Overall, nearly 50%
of all patients enrolled in care in our facility either died
or were LTFU during the observation period of 4 years.
Among these, nearly 80% of the attrition happened
during the first year. Key factors associated to attrition
were male sex, WHO clinical stage 3 or 4, low BMI, year
of enrollment 2010 and 2011, and ART status at the time
of presentation to the clinic.
This analysis describes a worrisome high attrition
rate within the first year of care, with a considerable
proportion of the events occurring during the first month
after enrollment in care. This is one of the highest
attrition rates reported from Mozambique as compared
to previous studies, which reported an attrition rate from
21% up to 26% (6, 11). Unlike previous studies from
Mozambique, which were conducted among all patients
living with HIV, this study focused on patients living
with HIV in advanced stages and with severe complica-
tions, which could partly explain the high attrition. While
the exact reasons are not clear, we discuss a few based
on our experience of working in the clinic.
First, the clinical and immunological profile of patients
in the center indicates that those who were in the very
advanced stages of their disease had a high risk of
mortality. Nearly 85% of the patients who visited the
facility were not initiated on ARTat the time of presenta-
tion andhad a median CD4 count of27 cells/ml, indicating
delays in diagnosis, enrollment into HIV care, and
initiation of ART despite enrollment. Studies have shown
that nearly 50% of all people living with HIV do not know
their HIV status (12). Given the generalized HIVepidemic
in Mozambique, innovative strategies to increase HIV test
uptake, including community-based HIV testing using
Table 2. Cumulative incidence (in %) of attrition among clients living with HIVand enrolled for care in Maputo, Mozambique,
20092011 (N1,657)
Period Cumulative number of attritions (N) Number of deaths Number of LTFU Cumulative incidence of attrition (95% CI)
1 month 298 38 260 18 (1620)
3 months 433 77 356 26 (2428)
6 months 522 97 425 32 (2934)
1 year 615 110 505 37 (3540)
2 years 731 125 606 45 (4348)
3 years 781 134 647 47 (4550)
4 years 793 137 656 48 (4550)
LTFU, lost to follow up; CI, confidence interval.
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Maputo, Mozambique, 20092011
Category Subcategory Unadjusted HR (95% CI) Adjusted HR (95% CI)
Sex Male 1.23 (1.01.4) 1.15 (1.01.3)
Female 1 1
Kaposi sarcoma Yes 1.26 (1.01.5) 1.01 (0.71.2)
No 1 1
WHO stage 1 1 1
2 0.97 (0.71.3) 1.23 (0.91.6)
3 1.45 (1.11.8) 1.30 (1.01.6)
4 2.10 (1.62.6) 1.91 (1.42.5)
BMI (kg/m
2) B16 1.91 (1.52.3) 1.51 (1.21.8)
1618.5 1.42 (1.11.7) 1.51 (1.21.8)
]18.5 1 1
ART status at presentation Yes 13.96 (11.716.5) 13.71 (11.416.4)
No 1 1
ART regimen First line 1 NA
Second line 0.74 (0.41.2)
Year of admission 2009 1 1
2010 1.14 (0.91.3) 1.29 (1.01.5)
2011 1.43 (1.21.6) 1.61 (1.31.9)
HR, hazard ratio; CI, confidence interval; WHO, World Health Organization; BMI, body mass index; ART, antiretroviral therapy.
Hazard ratios in bold font are statistically significant (P value less than 0.05).
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Fig. 1. KaplanMeier survival plots showing cumulative incidence of attrition by sex (1A), body mass index (1B), World Health
Organization Clinical Staging (1C), and year of enrollment (1D) among clients living with HIVand enrolled for care in Maputo,
Mozambique, 20092011.
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(page number not for citation purpose)point-of-care HIV tests, are urgently required, followed
by early entry into HIV care. Currently, ART programs
do not monitor pre-ART attrition, but systematically
providing attention on reducing pre-ART attrition may
prevent late presentations to care. Further, in order to
reduce the number of patients initiating ARTat advanced
disease stages, there is a need to adopt the new WHO
2013 ART guidelines, which recommend early initiation
of ART and change the threshold of ART initiation from
a CD4 count of 350 cells/ml to 500 cells/ml.
Second, the highest attrition rates were found among
those who were already receiving ART from elsewhere
at the time of presentation to the referral center. Nearly
three-fourths of them had advanced clinical disease,
and their attrition could in our study possibly represent
unrecorded deaths as has been showed by other studies
(13, 14). However, it is also possible that some of them
returned back to their original primary health facilities
for continuing HIV care or sought care at alternative
sources of ART, and hence represent ‘undocumented
transfers’ from the referral clinic. This could be over-
estimating the attrition rates observed in the study. Better
documentation of transfer out and deaths and further
investigation using qualitative methods are required to
understand the exact reasons of attrition in the first
month (15).
Third, our analysis showed that a number of indivi-
dual-level factors were independently associated with
attrition and merit special attention. Like in other studies
in Mozambique, in our multivariate analysis male sex was
associated with high attrition rates (11). Reasons for this
are unknown, but could be related to late presentation
to care, poor treatment adherence, and poor healthcare-
seeking behavior as reported in previous studies (16).
Specific interventions to reach men earlier could include
HIV-testing campaigns in the community, workplaces, or
sporting events.
Fourth, people who were malnourished were at a
higher risk of attrition, as has been reported from other
ART programs in sub-Saharan Africa. A recent study
from Mozambique examining clinic site-related factors
associated with attrition has shown that ART centers that
offered nutritional support services had better rates of
enrollment and retention (17). Highlighting the impor-
tance of nutritional support among patients living with
HIV attending our clinic and including a tailored
nutritional support in the package of care offered in the
health facility could contribute to improving the out-
comes of the program. Also, poor nutritional status with
subsequent deterioration of the immunological profile of
the patients living with HIV could predispose for severe
OIs, with tuberculosis (TB) being one of the most
common presentations. The burden of TB during early
HIV care is particularly heavy in sub-Saharan African
settings, where this presents a major challenge in treat-
ment programs. An important proportion of patients
living with HIV and with asymptomatic TB (or TB with
minimal symptoms) are not clinically recognized until
immune recovery triggers the development of symptoms
during early ART (18, 19). Innovative strategies for
intensive investigations of OI, which include intensified
TB case finding, the use of new diagnostics tools like the
Xpert MTB/RIF assay or the new assay that detects
mycobacterial lipoarabinomannan (LAM) antigen pre-
sent in urine, and presumptive or empirical TB treatment
prior to starting ART, should be considered in this setting
in order to develop a more integrated healthcare delivery
for TB, HIV, and other OIs (20).
Finally, the patients enrolled in care in 2010 and
2011 had higher attrition rates than in 2009. This could
possibly be related to strict implementation of referral
criteria in July 2010, thus resulting in a situation wherein
only patients living with HIV who experience complica-
tions are enrolled into care.
Our analysis has several strengths. First, we used
routinely collected program data, and hence the findings
reflect the realities in the field. Second, as mentioned
earlier, this study provides information specifically on
severely immune-compromised patients living with HIV
who were enrolled in an intermediary-level health facility,
whereas most other reports were focused mainly on over-
all ART programs. Third, we followed the strengthening
the reporting of observational studies in epidemiology
(STROBE, 21) guidelines for reporting of observational
studies, including ethics.
There were a few limitations mainly related to the
operational nature of the study. First, data were missing
in a substantial proportion of patients on key variables
like CD4 count at admission and BMI. The lack of CD4
count could be partially explained by the limited access
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with the CD4 testing facility available only in the
laboratory of the Maputo Central Hospital. In addition,
the laxity in documentation of CD4 data in the electronic
register or the medical files may have contributed to the
missing data. Urgent measures are required, includ-
ing sensitizing the clinic staff about the importance of
recording and reporting and strengthened supervision
and monitoring. Second, we may be overestimating
attrition. As mentioned earlier, we could not document
the exact final outcomes of LTFU. It is possible that
many of these could be on HIV care from other facilities
and hence are poorly documented. Third, we could not
identify the exact reason of attrition. Future research,
including qualitative methods (with in-depth patient
interviews), is needed for a better understanding of the
reasons for attrition. Since most of the patients have
access to a mobile phone, this could be used not only for
tracking of LTFU cases, but also to reinforce messages
and prevent LTFU.
Conclusions
We identified that overall attrition rates among patients
living with HIVand enrolled into care at the intermediary
referral center in Maputo were high, and were mainly
related to advanced stage of clinical disease. Urgent
measures are required to address this, including develop-
ing innovative ways of increasing HIV test uptake,
adopting the new WHO 2013 criteria for ART initiation,
providing nutritional supplementation in the package of
care, and providing special attention to men and those
who are already on ART elsewhere at the time of
presentation to the clinic. Qualitative research is required
to understand the exact reasons of LTFU and to design
informed evidence-based interventions.
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